Kornimate/medical-research-clean huggingface dataset:
renal denervation in patient undergoing vt ablation:combined renal denervation and vt ablation vs. simply vt ablation

Conditions: Ventricular Tachycardia; Cardiomyopathy

Summary: study hypothesis: with optimal medical therapy and repeated ablations, an additional renal denervation may have protective effects in terms of vegetative intrinsic activity and lead to a significant reduction in vt burdens. study design: multicenter, randomized, prospective, single-blind clinical trial.

study protocol: catheter ablation of ventricular tachycardia versus combined catheter ablation of ventricular tachycardia and renal denervation. a total of 50 patients with ventricular tachycardia treated with icd shocks or atp will be enrolled in this study. the randomization in the study is done before ablation. for the ablation, an arterial access is required in both groups. during a 30 minutes waiting time which will apply to both groups, renal denervation will be performed. in this period of time operators and staff will be blinded for the procedure, thereby they won't know if the patients will receive a renal denervation, in that way the investigators are avoiding a bias of future treatment of the patients. follow up and repeat procedures: all patients will be followed for a period of 3, 6, 9, 12 and 18 months after the procedure. regular visits are done in the investigators office. the visit will include icd interrogation, vt documentation in icd holter, 24-hour holter ecg or tele-ecgs, echocardiography. re- vt ablations are allowed at any time. in case of renal artery stenosis, denervation will not be performed. drug therapy can be continued.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * ischemic cardiomyopathy * nyha ii-iii * recurrent ventricular tachycardia, icd interventions (shock or atp) * obtained written informed consent exclusion criteria: * age \<18 years * previous vt ablation * nyha iv * cardiopulmonary decompensation within the last 4 weeks * pregnant women or women of childbearing potential without a negative pregnancy test within 48 hours prior to treatment * history of hemorrhagic diathesis or other coagulopathies * contraindication for oral anticoagulation * hyper- or hypothyroidism * drug or chronic alcohol abuse * has any condition that would make participation not be in the best interest of the subject * incompliance
comparison of postoperative analgesic effectiveness of superficial and deep serratus plane blocks for mastectomy

Conditions: Mastectomy; Postoperative Pain; Analgesia

Summary: pain after breast surgery can be quite severe and can significantly affect quality of life. by successfully treating acute pain, it is aimed to prevent the formation of pain memory and to ensure that chronic pain never occurs. it is known that by using regional techniques, the use of general anesthetics and opioids can be reduced and their harmful effects can be limited. in this study, it will be compared the analgesic effectiveness of superficial and deep serratus plane blocks in the postoperative acute and chronic periods.

acute and chronic pain is a serious problem in patients undergoing breast surgery. apart from the feeling of pain, it also causes psychological difficulties, increased hospital stays, delays or difficulties in mobilization, and so on. due to all these reasons, postoperative pain control is very important. although opioids are the gold standard in the treatment of pain, their side effect profiles (sedation, respiratory depression, constipation, tolerance development, etc.) limit their use and different searches are on the agenda. there are studies showing that superficial and deep serratus plane blocks are effective in mastectomy operations. in this study, patients who underwent mastectomy these two blocks will be compared to see which one is superior and to investigate the differences that may occur in the acute and chronic periods. after general anesthesia induction, a superficial serratus plane block will be performed on the first group of patients undergoing surgery by applying local anesthetic to the fascia between the serratus anterior and latissimus dorsi muscles at the level of the 4th and 5th ribs under ultrasound. then the patient will undergo surgical procedure. likewise, for the second group of patients, after general anesthesia induction, a deep serratus plane block will be performed by applying local anesthetic between the rib and the serratus anterior muscle at the level of the 4th and 5th ribs, under ultrasound guidance, and the patient will be taken into surgery. both groups of patients will be monitored for 24 hours after the operation with a patient-controlled analgesia device. patients' pain scores, satisfaction scores, nausea and vomiting scores, and additional analgesic needs will be recorded 24 hours postoperatively.

Eligibility criteria:
inclusion criteria: * patients who will undergo mastectomy surgery * patients who agreed to participate in the study * asa i-ii patients exclusion criteria: * patients planned for bilateral breast surgery * patients who have had previous breast surgery * patients with existing neuropathic pain or receiving treatment for neuropathic pain * patients with psychiatric disorders * patients with opioid addiction * patients allergic to local anesthetics

Keywords: serratus anterior plane block local anesthetic regional anesthesia postoperative analgesia
invasiveness and chemoresistance of cancer stem cells in colon cancer

Conditions: Colorectal Neoplasms

Summary: the main objective of this study is to identify and characterize subpopulations of cells with invasive capacity in colorectal cancer from primary tumor, blood and metastatic samples.

secondary objectives include: * determine the intrinsic properties essential for the dissemination and chemoresistance of these cells capable of initiating tumors * identify a "molecular signature" for potential invasiveness and chemoresistance of cells initiating metastases. * describe the evolution of patients during 24 months of follow up and correlations with observed cellular profiles. * enrich the tumor bank of the institution.

Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * patient with adenocarcinoma-type colorectal cancer: * stage iii at diagnosis, surgical resection of the primary tumor proposed. * stage iv at diagnosis, surgical resection of the primary tumor and possibly of metastases proposed. * stage iv who have already undergone surgical excision of the primary tumor, and for whom metastasectomy is now proposed. exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * patients for whom surgical resection of the primary tumor is not considered as an option * pstage iv at diagnosis, but metastasectomy is not considered as an option * patients with positive hiv, hepatitis b or hepatitis c serology

Keywords: invasive potential molecular characterisation of circulating cells
beta testing of a smartphone app for hiv prevention in malaysian msm

Conditions: HIV Prevention Program

Summary: this project will involve beta testing of the jomprep app to assess its usability and acceptability among malaysian msm.

given the evolving hiv epidemic among msm and their challenges with accessing prevention services, we previously proposed to adapt, expand, and refine an existing app (namely the healthmindr app) to deliver an integrated hiv prevention intervention that will promote hiv testing and linkage to prep and that incorporates screening and support for p/sud for malaysian msm. we now plan to conduct expanded beta testing of the newly designed jomprep app to assess its usability and acceptability among malaysian msm. following wireframing and usability testing, keymind (an experienced mobile app development company that has significant experience in building hipaa-compliant apps, including healthmindr) will apply a user interface (ui) design (i.e., colors/branding) to the interactive prototype, followed by the final development of the app (beta version). the objective of this study is to beta test this app to identify potential bugs and to ensure its usability in a real-world setting. as part of the expanded beta testing, we will also evaluate the design, functionality, and usability of the jomprep app. this step is a critical stage of app development and will increase the ability of our research team to develop an acceptable and effective app.

Eligibility criteria:
inclusion criteria: * hiv-negative msm * age more than or equal to 18 * cis-gender men * condomless sex in the last 30 days * own a smartphone exclusion criteria: * unable to provide informed consent * unable to read and understand english or bahasa malaysia

Keywords: prep mhealth mobile application
effects of pnf on shoulder pain in paraplegic manual wheel chair users

Conditions: Shoulder Impingement

Summary: this project was a randomized control trial conducted to check the effects of proprioceptive neuromuscular facilitation on shoulder pain due to chronic impingement syndrome in paraplegic manual wheelchair users after spinal cord injury so that we can have best treatment option for patients with shoulder pain due to manual wheelchair usage. duration was of 6months,convenient sampling was done, subject following eligibility criteria from spine welfare trust center, nawaz sharif social security hospital were randomly allocated in two groups via lottery method, group a participants were given baseline treatment along with pnf exercises , group b participants were given baseline treatment upto 6 weeks and 3 sessions per, post intervention assessment was done after 6 weeks, by self-generated questionnaire (wuspi) wheel chair users shoulder pain index, (srq) shoulder rating questionnaire and physical assessment by 2 special test was done, data was analyzed by using spss version 25.

in paraplegic manual wheelchair users shoulder pain is most common problem after spinal cord injury. due to wheelchair propulsion, weight relief task and other household activities repetitive load induced on upper limb and put substantial load in particular on shoulder.in spinal cord injured patients shoulder pain is because of over use of upper limb and shoulder during wheelchair related activities and personal care activities. less stability and slight muscle mass leads toward pain in their life at some point because of muscular imbalance and later on shoulder secondary impingement syndrome. this study compared the rhythmic stabilization technique from pnf exercises with conventional treatment on experimental and control group to see the difference in reduction of pain and disability.

Eligibility criteria:
inclusion criteria: * 18-60 years old paraplegic manual wheel chair users after spinal cord injury. * those having level of injury from c7-t12 * patients who are using wheelchair from more than one year. * pain perceived region of one or both shoulder from last three months or more * pain without radicular symptoms radiating to whole upper limbs. * wheelchair propulsion in activities of daily living, * individuals with positive neer's test and hawkins-kennedy test exclusion criteria: * any red flags (tumor, fracture, metabolic diseases, rheumatoid arthritis, resting blood pressure greater than 140/90 mmhg, prolonged history of steroid use, etc. * any dislocation ,muscular tear and acute problem of shoulder. * presented with a diagnosis of cervical spinal stenosis, exhibited bilateral upper extremity symptoms * any recent surgery of the shoulder * individuals using other mobility devices with wheelchair. * individuals with primary impingement

Keywords: spinal cord injury, wheelchair users, shoulder pain, pnf
health outcomes in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this research is being done to help us learn about how different factors related to treatment affect rheumatoid arthritis (ra). this is not a treatment study. we will follow the patient for one year as he or she receives usual treatment from his or her rheumatologist. up to 360 adults with ra may join this study.


Eligibility criteria:
inclusion criteria: * males and females age 19 or older * current active, adult-onset rheumatoid arthritis who meet american college of rheumatology (acr) criteria for ra and have: (acr functional class i-iii), defined as: * 3 or more swollen or tender joints and * morning stiffness of 45min or longer * or judged by their rheumatologist to have active disease * no evidence of other inflammatory diseases (e.g., crohn's, ibs) * functional class i, ii or iii exclusion criteria: * individuals with significant cardiovascular disease (chf, stroke, mi) * unwilling to have medications monitored and/or comply with protocol * not fluent in english * planning to move from area within next year or change health insurance (which would preclude ongoing care by a johns hopkins rheumatologist) * enrolled in study evaluating efficacy of new or existing ra medications

Keywords: rheumatoid arthritis mood adherence medication
clinical safety study of the progesterone vaginal ring in women undergoing assisted reproductive technology procedures

Conditions: Progesterone Supplementation in Women Undergoing ART

Summary: the purpose of the study is to assess the safety of progesterone vaginal ring (pvr) in women undergoing fresh embryo transfer (art).


Eligibility criteria:
inclusion criteria: * pre-menopausal women aged 18-34 at the time of consent. * documentation of a normal uterine cavity by hysteroscopy, hydrosonogram, or hysterosalpingogram within one year of screening. * normal pap smear test within 24 months of screening. * at least one cycle without reproductive hormone medication prior to screening follicle-stimulating hormone (fsh) and estradiol blood draw. * tubal, idiopathic, male factor, ovulatory dysfunction, or endometriosis-linked infertility. exclusion criteria: * body mass index greater than 38 kg/m\^2. * fsh greater than 15 iu/l during the early follicular phase (day 2-4). for those participants with polycystic ovarian syndrome, a day 2-4 fsh level can be obtained following a progestogen withdrawal or spontaneous menses. * clinically significant gynecologic pathology, such as submucosal fibroids, intramural fibroids \>5 cm, communicating hydrosalpinx, uncorrected uterine septum, endometrial cancer or endometrial atypia, scar tissue inside the cavity or poorly developed uterine lining from prior uterine surgery, pelvic tuberculosis, or any other conditions that could adversely affect pregnancy success. * uncontrolled elevation of prolactin or too little thyroid hormone in the blood. * history of more than one failed fresh in vitro fertilization cycle. a failed cycle is defined as having started a cycle and not becoming pregnant or pregnancy loss prior to the 20th week of pregnancy.

Keywords: progesterone vaginal ring (pvr) vaginal progesterone ring assisted reproductive technology (art) infertility
the role of the intestinal microbiome in enteric and systemic vaccine immune responses

Conditions: Rotavirus Infections; Intestinal Bacteria Flora Disturbance; Reaction - Vaccine Nos; Tetanus; Streptococcal Pneumonia

Summary: the purpose of this study is to evaluate if the intestinal microbiota influences rotavirus vaccine immune responses in healthy adult volunteers.

this study will alter the intestinal microbiota in healthy adults using antibiotics and subsequently measure immune reactions to the rotavirus vaccine (rotarix), the tetanus vaccine and the pneumococcal vaccine (pneumo23).

Eligibility criteria:
inclusion criteria: * healthy, as determined by a responsible physician, based on a medical evaluation including medical history, physical examination and laboratory tests carried out within 28 days prior to starting antibiotics (day -98). a subject with a clinical abnormality or laboratory parameter outside the reference range may be included if the investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures * male between 18 and 35 years of age, inclusive at the time of signing the informed consent * capable of giving written informed consent and able to comply with the requirements and restrictions listed in the informed consent form * normal defecation pattern (defined as ≤3x/ day and ≥3x/week) exclusion criteria: * subject has had a major illness in the past 3 months or any significant chronic medical illness that the investigator would deem unfavorable for enrollment, including inflammatory diseases. * subject with any history of immunodeficiency * subjects with a history of any type of malignancy * subject with a history of thrombocytopenia or bleeding disorder * subject has a past or current gastrointestinal disease which may influence the gut microbiota * current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of gilbert's syndrome or asymptomatic gallstones) * history of alcoholism and/or drinking more than an average of 5 units of alcohol per day * the subject has received an investigational product within three months of day 0 of the current study
study of exablate model 4000 type 1.0/1.1 following the treatment of neuropathic pain

Conditions: Peripheral Neuropathy; Neuropathic Pain

Summary: the exablate 4000 obtained ce mark for the treatment of neuropathic pain in december 2012. the purpose of this post market study is to obtain real world data on the safety and performance of the exablate treatment for neuropathic pain. the objective of this study is to capture the change in pain intensity, physical/emotional function, and pain impact for patients diagnosed with neuropathic pain who undergo an exablate treatment.

the purpose of this post market study is to obtain real world data on the safety and performance of the exablate treatment for neuropathic pain.

Eligibility criteria:
inclusion criteria: * men and women age 30 years or older * subject undergoing an exablate procedure for their planned neuropathic treatment per local institution standard of care * subject has diagnosis of "definite" neuropathic pain (grading system iasp-neupsig) * patient has a score of 6 or higher on the numeric rating scale (nrs) * subject has tried and failed at least three documented medically supervised treatments (including, but not limited to physical therapy, acupuncture, etc.) and has failed medication treatment from at least two different medication classes * subject's pain-related medication regimen is stable 4 weeks prior to the baseline evaluation * subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all study visits exclusion criteria: * subject diagnosed with a nociceptive chronic pain syndrome * subject does not agree to participate or is unlikely to participate for the entirety of the study * subject is currently participating in another clinical investigation with an active treatment arm
study comparing intravenous (iv)/subcutaneous (sc) risankizumab to iv/sc ustekinumab to assess change in crohn's disease activity index (cdai) in adult participants with moderate to severe crohn's disease (cd)

Conditions: Crohn's Disease (CD)

Summary: crohn's disease (cd) is a long-lasting condition causing inflammation that can affect any part of the gut. this study will evaluate how well risankizumab works compared to ustekinumab. this study will assess change in crohn's disease activity index (cdai). risankizumab is an investigational drug being developed for the treatment of crohn's disease (cd). ustekinumab is an approved drug for the treatment of moderate and severe cd. participants are randomly assigned to one of the three treatment groups. each group receives a different treatment. there is a 1 in 2 chance that participants will be assigned to ustekinumab. around 508 adult participants with moderate to severe cd will be enrolled in approximately 307 sites worldwide. in part 1, participants assigned to risankizumab will receive intravenous (iv) doses of risankizumab at week 0, 4,8 and subcutaneous (sc) doses every 8 weeks thereafter through week 48. participants assigned to ustekinumab will receive intravenous (iv) dose of ustekinumab at week 0 and subcutaneous (sc) doses every 8 weeks thereafter through week 48. in part 2, participants who received risankizumab in part 1 and completed the week 48 visit will continue to receive sc risankizumab for up to an additional 220 weeks. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will attend regular visits during the study at a hospital or clinic. the effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of crohn's disease (cd) for at least 3 months prior to baseline. * crohn's disease activity index (cdai) score 220 - 450 at baseline. * confirmed diagnosis of moderate to severe crohn's disease as assessed by stool frequency (sf), abdominal pain (ap) score, and simple endoscopic score for cd (ses-cd). * demonstrated intolerance or inadequate response to one or more anti-tumor necrosis factor (tnf) therapies. exclusion criteria: * current diagnosis of ulcerative colitis or indeterminate colitis. * receipt of cd approved biologic agents prior to baseline (as detailed in protocol), or any investigational biologic or other agent or procedure prior to baseline (as detailed in protocol). * prior exposure to p19 and/or p40 inhibitors (e.g., risankizumab and ustekinumab). * currently know complications of cd (strictures, short bowel, etc).

Keywords: crohn's disease (cd) risankizumab ustekinumab skyrizi
a prospective study on the"management of hypertension in young and middle-aged subjects in enterprises setting"

Conditions: Hypertension; Blood Pressure

Summary: in recent years, with the investment from government in the health management of the elderly, community management of hypertension in the elderly has made great progress in management rate and standardized management, but the management of young and middle-aged patients with hypertension is still blank. workplace pressure measurement may be more suitable for most of the young and middle-aged patients to find high blood pressure and monitor blood pressure changes in time. however, there is not much research on workplace pressure measurement. whether blood pressure measurement in the workplace can reduce the white coat effect, and how it relates to home blood pressure and ambulatory blood pressure is still unclear.


Eligibility criteria:
inclusion criteria: 1. male and female sex, aged 18-65 years 2. three different daytime workplace blood pressure measurements meet the limits: systolic blood pressure ≥ 120 mmhg, or diastolic blood pressure ≥80 mmhg 3. hypertensive patients who are taking antihypertensive drugs 4. willing to provide information about disease history and lifestyle 5. willing to receive follow-up for up to 2-3 years 6. sign the informed consent exclusion criteria: 1. having the onset of cardiovascular and cerebrovascular diseases such as stroke, myocardial infarction or heart failure within 6 months 2. having a history of atrial fibrillation or frequent arrhythmia 3. complicating other diseases that are not suitable for the trial, such as thyroid disease with active medication, acute infectious diseases, chronic mental illness, and tumors 4. the subject is participating in other clinical studies.